Open AccessNovel Formulations of Buprenorphine for Treatment of Opioid Use Disorder
Author(s) -
Richard N. Rosenthal
Publication year - 2019
Publication title -
focus/focus (american psychiatric publishing. online)
Language(s) - English
Resource type - Journals
eISSN - 1541-4108
pISSN - 1541-4094
DOI - 10.1176/appi.focus.20180043
Subject(s) - buprenorphine , opioid use disorder , medicine , heroin , fentanyl , psychosocial , opiate substitution treatment , opioid , intensive care medicine , psychological intervention , psychiatry , drug , anesthesia , receptor
Opioid use disorder (OUD) is epidemic in the United States. In addition to medical, economic, and social impairments, risk of overdose fatality is high. In 2017, there were 14,958 deaths from natural or semisynthetic opioids, 15,958 from heroin, and 29,406 from synthetic opioids, such as fentanyl. Psychosocial interventions do not add substantial efficacy to medical OUD treatments, and thus making evidence-based OUD treatments more accessible is urgent. However, considerable diversion of oral and transmucosal opioid maintenance medications has been documented. Delivery systems that reduce risks of nonadherence through diversion or altered self-administration may increase buprenorphine's effectiveness for clinical stabilization via increased treatment exposure. The article presents findings from multisite efficacy studies of two subcutaneous depot buprenorphine formulations and a long-acting implant. Novel delivery systems show promise in providing improved outcomes through intermediate- and long-acting exposure to medication while reducing the risk of medication nonadherence, diversion, and accidental exposure.